Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn

RS, Abecassis MM, et al. Diagnosis, Staging,

and Management of Hepatocellular Carcinoma:

Practice Guidance by the American

Association for the Study of Liver Diseases.

Hepatology. 2018. 68: 723-750.

Sieghart W, Hucke F, Peck - Radosavljevic M.

Transarterial chemoembolization: modalities,

indication, and patient selection. J Hepatol.

62: 1187-95.

EASL. EASL Clinical Practice Guidelines:

Management of hepatocellular carcinoma. J

Hepatol. 2018. 69: 182-236.

Llovet JM, Real MI, Montaña X, Planas R,

Coll S, Aponte J, et al. Arterial embolisation

or chemoembolisation versus symptomatic

treatment in patients with unresectable

hepatocellular carcinoma: a randomised

controlled trial. Lancet. 2002. 359: 1734-9.

Lencioni R, de Baere T, Soulen MC, Rilling

WS, Geschwind JF. Lipiodol transarterial

chemoembolization for hepatocellular

carcinoma: A systematic review of efficacy and

safety data. Hepatology. 2016. 64: 106-16.

Ichikawa T, Machida N, Sasaki H, Tenmoku A,

Kaneko H, Negishi R, et al. Early Prediction

of the Outcome Using Tumor Markers and

mRECIST in Unresectable Hepatocellular

Carcinoma Patients Who Underwent

Transarterial Chemoembolization. Oncology.

91: 317-330.

Gaba RC, Lokken RP, Hickey RM, Lipnik

AJ, Lewandowski RJ, Salem R, et al. Quality

Improvement Guidelines for Transarterial

Chemoembolization and Embolization of

Hepatic Malignancy. J Vasc Interv Radiol. 2017.

: 1210-1223 e3.

Llovet JM , Lencioni R. mRECIST for HCC:

Performance and novel refinements. J Hepatol.

72: 288-306.

Younes EH, Zahra HF, Soumaya BM, Maria L,

Nada L, Hakima A, et al. Study of predictive factors

of complete response after chemoembolization

for unresectable hepatocellular carcinoma in 162

patients. Clin Exp Hepatol. 2020. 6: 313-320.

Domaratius C, Settmacher U, Malessa C,

Teichgraber U. Transarterial chemoembolization

with drug - eluting beads in patients with

hepatocellular carcinoma: response analysis with

mRECIST. Diagn Interv Radiol. 2021. 27: 85-93. 11. Vesselle G., Quirier-Leleu C., Velasco S.,

Charier F., Silvain C., Boucebci S., et al.

Predictive factors for complete response of

chemoembolization with drug - eluting beads

(DEB-TACE) for hepatocellular carcinoma. Eur

Radiol. 2016. 26: 1640-1648.

Dioguardi Burgio M., Sartoris R., Libotean C.,

Zappa M., Sibert A., Vilgrain V., et al. Lipiodol

retention pattern after TACE for HCC is a predictor

for local progression in lesions with complete

response. Cancer Imaging. 2019. 19: 75.

Wang CY, Li S. Clinical characteristics and

prognosis of 2887 patients with hepatocellular

carcinoma: A single center 14 years experience

from China. Medicine (Baltimore). 2019. 98:

e14070.

Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen

L, et al. Treatment of hepatocellular carcinoma

with portal vein tumor thrombus: advances and

challenges. Oncotarget. 2017. 8: 33911-33921.

Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini

A, Pompili M, Ponziani FR. Treatment of

hepatocellular carcinoma in patients with portal

vein tumor thrombosis: Beyond the known

frontiers. World J Gastroenterol. 2019. 25:

-4382.